AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 11 min read$AVR

L1 Capital Pty Ltd sold $69K of AVR (indirect holdings)

L1 Capital Pty Ltd sold 7,800 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $8.83 on 2026-08-28.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Sep 1, 2026, 10:24 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 10:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The disclosed sale provides transparency but is unlikely to affect AVR price materially.

02

Market read

Small insider sale; limited trading relevance.

03

What to watch

The sale was on an open market, not a pre‑arranged 10b5‑1 plan, which may indicate discretionary intent.

Relevance 3/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital sold 7,800 AVR shares for $68,874, reducing its indirect holdings to 4,803,541 shares.

Expected impact

Minimal short‑term downward pressure, likely within normal volatility.

Evidence & confidence

Sale size (~$69K) is small relative to market cap; insider still holds a large position, so market impact is limited.

Market effects

Sector

No immediate sector-wide effect; AVR operates in medical device/diagnostics sector.

Regional

U.S. market only; no regional ripple.

Global

Limited to investors tracking AVR insider activity.

Counterpoint

What could challenge this read

If the insider is reducing exposure, it could signal concerns about near‑term performance.

Key entities

  • company
    Anteris Technologies Global Corp.

    Issuer of the AVR ticker.

  • insider
    L1 Capital Pty Ltd

    10% owner selling shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVR insider trading history →

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min